Eagle Bay Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Eagle Bay Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23	Closed	-$3.2K	–	179
2024 Q4	$3.2K	Hold	23	–	–	﹤0.01%	781
2024 Q3	$3.47K	Hold	23	–	–	﹤0.01%	1111
2024 Q2	$3.17K	Hold	23	–	–	﹤0.01%	813
2024 Q1	$3.52K	Hold	23	–	–	﹤0.01%	801
2023 Q4	$2.93K	Hold	23	–	–	﹤0.01%	706
2023 Q3	$2.18K	Hold	23	–	–	﹤0.01%	754
2023 Q2	$2.08K	Buy	23 +12	+109%	+$1.04K	﹤0.01%	754
2023 Q1	$1.21K	Hold	11	–	–	﹤0.01%	806
2022 Q4	$1.38K	Hold	11	–	–	﹤0.01%	805
2022 Q3	$1K	Hold	11	–	–	﹤0.01%	800
2022 Q2	$1.05K	Buy	+11	New	+$1.04K	﹤0.01%	906

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eagle Bay Advisors's ASND Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 23 shares — an estimated $3.2K sold.

Eagle Bay Advisors first reported a position in ASND in Q2 2022 and held it in 11 quarters. The position peaked at $3.52K in Q1 2024. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

Eagle Bay Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 23 Ascendis Pharma A/S shares in Q1 2025, an estimated $3.2K.
Eagle Bay Advisors first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 11 quarters.
Eagle Bay Advisors's Ascendis Pharma A/S position peaked at $3.52K in Q1 2024.
244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.